Ensartinib
98%
- Product Code: 108209
CAS:
1365267-27-1
| Molecular Weight: | 547.41 g./mol | Molecular Formula: | C₂₅H₂₅Cl₂FN₆O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Ensartinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly for patients whose tumors have specific genetic mutations, such as ALK (anaplastic lymphoma kinase) rearrangements. It functions as an ALK inhibitor, targeting and blocking the activity of the ALK protein, which is involved in the growth and spread of cancer cells. By inhibiting this protein, ensartinib helps to slow down or stop the progression of the disease. It is often prescribed for patients who have developed resistance to other ALK inhibitors or as a first-line treatment option. The drug is administered orally, making it convenient for patients to use on a regular basis. Clinical trials have shown that ensartinib can be effective in shrinking tumors and improving progression-free survival in patients with ALK-positive NSCLC.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿26,091.00 |
+
-
|
Ensartinib
Ensartinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly for patients whose tumors have specific genetic mutations, such as ALK (anaplastic lymphoma kinase) rearrangements. It functions as an ALK inhibitor, targeting and blocking the activity of the ALK protein, which is involved in the growth and spread of cancer cells. By inhibiting this protein, ensartinib helps to slow down or stop the progression of the disease. It is often prescribed for patients who have developed resistance to other ALK inhibitors or as a first-line treatment option. The drug is administered orally, making it convenient for patients to use on a regular basis. Clinical trials have shown that ensartinib can be effective in shrinking tumors and improving progression-free survival in patients with ALK-positive NSCLC.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :